![](/img/cover-not-exists.png)
2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)
J.Y. Douillard, E.S. Kim, V. Hirsh, T. Mok, M. Socinski, R. Gervais, L.Y. Wu, L. Li, M. Sellers, E. LoweVolume:
5
Year:
2007
Language:
english
DOI:
10.1016/s1359-6349(07)70095-2
File:
PDF, 39 KB
english, 2007